Monitoring of KRAS-mutated ctDNA to discriminate pseudo-progression from true progression during anti-PD-1 treatment of lung adenocarcinoma

OBJECTIVES: Pseudo-progression is a rare but worrying situation for both clinicians and patients during immunotherapy. Dedicated ir-RECIST criteria have been established to improve this situation. However, this can be sometimes considered inadequate and patients experiencing true progression may the...

Descripción completa

Detalles Bibliográficos
Autores principales: Guibert, Nicolas, Mazieres, Julien, Delaunay, Myriam, Casanova, Anne, Farella, Magali, Keller, Laura, Favre, Gilles, Pradines, Anne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5514971/
https://www.ncbi.nlm.nih.gov/pubmed/28445137
http://dx.doi.org/10.18632/oncotarget.16935

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5514971/
https://www.ncbi.nlm.nih.gov/pubmed/28445137
http://dx.doi.org/10.18632/oncotarget.16935

Ejemplares similares